Alterity Therapeutics received approval from an independent data monitoring committee to proceed with its ATH434-201 Phase 2 clinical trial for early-stage multiple system atrophy without modifications.

The commitee's second review found no safety concerns with ATH434, signalling a positive step in addressing the lack of treatments for MSA.

The 12-month trial, set to conclude in November, is a randomised, double-blind, placebo-controlled study with top-line data expected by January 2025.

The evaluation includes neuroimaging and protein biomarkers, supporting future Phase 3 studies.